A practical, evergreen set of records and questions for assessing claims about Casa Santa Isabel Ibogaine Clinic. The purpose is not to infer a clinic’s status, but to identify what can be independently checked before any decision is made.
Use this page as a sequence of verification steps, not as a scorecard. A facility may describe strong practices, but a prospective patient or family member should be able to request the underlying record, understand who issued it, and confirm it through an independent channel. For broader context on evaluating ibogaine safety claims, Rosarithm’s main safety overview frames the same evidence-first approach.
Ask what local licensing, registration, business authorization, or health-related operating documents are relevant to the location and services described. Request copies that show an issuing authority, effective dates, scope, and a route for checking current status.
Ask for the relevant registration or licensing documents, then look for the regulator or registry that issued them. A document without an issuer, date, registration number, or jurisdiction is difficult to verify. The legal standing of health facilities and businesses varies by place, so the record should match the actual location and the services being described.
Request the name and role of the person responsible for clinical decisions during screening, dosing, monitoring, and emergencies. Credentials should be verifiable through the relevant licensing board or credentialing body, not only through a biography supplied by the facility. The Federation of State Medical Boards directory illustrates the kind of official route used to identify a U.S. state medical board; equivalent local authorities matter where treatment would occur.
If a clinic refers to hospital relationships, professional memberships, or external clinical support, ask for the institution or body to confirm the relationship directly. A logo, testimonial, or unsupported association is not the same as a verifiable affiliation. For people comparing locations, an overview of ibogaine treatment centers in the United States can also help keep questions focused on the actual jurisdiction.
Ask how screening findings inform a dosing rationale, who reviews medication and substance-use history, what monitoring equipment is used, and who is present and qualified to respond if a patient’s condition changes. The term electrocardiography refers to recording the heart’s electrical activity; if cardiac monitoring is claimed, request a clear explanation of what is measured, when it is measured, and who interprets it.
Safety claims are most meaningful when they include a clear route for escalation. Ask to see the written emergency response process, incident-reporting policy, and a realistic description of what happens if monitoring identifies a concern or transfer becomes necessary.
Ask how adverse events, near misses, transfers, and unexpected outcomes are documented, reviewed, and communicated. The World Health Organization’s patient safety policy work reflects why systems for reporting and learning matter: a safety statement is more credible when it identifies how concerns are recorded and used to improve practice.
Request the written plan for emergency transport and hospital transfer, including the receiving facility or emergency pathway where that can appropriately be disclosed. Do not treat a verbal statement as confirmation of an agreement. If a hospital relationship is claimed, seek third-party confirmation from the named institution through its official channels.
Ask how the clinic documents medication review, stabilization, and the timing of any treatment decisions. People considering a transition from opioid medication should keep questions specific; methadone and ibogaine considerations require careful, individualized review rather than a one-size-fits-all timeline. Likewise, claims about managing ibogaine withdrawal experiences should be tied to a written assessment and escalation process.
A clinic may have reasons not to disclose private patient information, but that is different from being unable or unwilling to identify the applicable policy, responsible role, issuing authority, or method of verification. Pause when answers rely on urgency, exclusivity, or broad reassurance instead of records that can be checked.
Ask what outcome is being measured, over what period, by whom, and whether there is a defined denominator. Stories of change can be meaningful to individuals, but they do not by themselves establish a safety profile, expected result, or likelihood of benefit.
Ask whether the claim distinguishes completed treatment from follow-up, whether complications or transfers are included, and whether the method is documented. An ibogaine anti-addiction claim should be read as a claim requiring context, not as a substitute for records on screening, follow-up, and limitations.
Ask for the post-treatment plan in writing: who makes contact, what warning signs prompt urgent help, how existing clinicians are involved where appropriate, and what continuity support is offered. A program that treats follow-up as optional marketing language should be questioned carefully.
Use public registries for licenses where available, contact credentialing bodies using independently found details, and seek confirmation from a named hospital or institution rather than through the clinic. Our clinical standards framework can help organize those questions across screening, monitoring, and care continuity.
Claims about identity, insight, or transformation are hard to verify as clinical outcomes. Discussions of ibogaine and ego may describe personal experience, but they should not be presented as evidence that replaces documented safety procedures or follow-up plans.
Save documents, note who made each statement, and use independent channels for confirmation. Cross-border care can add practical complexity, so those assessing options can also consider the questions raised by ibogaine treatment beyond Mexico before treating any assurance as settled.